Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels

Hiroyuki Sugiura, Ken-ichi Matsuoka, Yasuhisa Sando, Yusuke Meguri, Shuntaro Ikegawa, Makoto Nakamura, Miki Iwamoto, Takanori Yoshioka, Takeru Asano, Eisei Kondo, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

Research output: Contribution to journalArticle

Abstract

Mogamulizumab (Mog), a humanized anti-CCR4 antibody, provides an important treatment option for relapsed/refractory adult T cell leukemia/lymphoma. However, administration of Mog before allogenic hematopoietic stem cell transplantation has been reported to be a risk factor for severe acute graft-versus-host disease (GVHD). The etiological hypothesis is Mogamulizumab may eradicate CCR4-positive regulatory T cells (Tregs). Theoretically, Treg homeostasis and course of GVHD can be affected by plasma exchange (PE) with decreasing plasma Mog concentration. Here, we present a case of severe acute GVHD after pretransplantation Mog, in which PE was performed for liver failure. As a result, plasma Mog concentration was decreased but it did not lead to the prompt elevation of Treg levels in peripheral blood and clinical responses of GVHD were limited to partial remission. Our case suggests that recovery of donor-derived Treg in the acute phase after HSCT is multifactorial and the single procedure of PE-based Mog depletion does not necessarily warrant the quick restoration of Treg homeostasis.

Original languageEnglish
JournalTransfusion and Apheresis Science
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Plasma Exchange
Graft vs Host Disease
Homeostasis
Antibodies, Monoclonal, Humanized
Adult T Cell Leukemia Lymphoma
Hematopoietic Stem Cell Transplantation
Liver Failure
Regulatory T-Lymphocytes
mogamulizumab
Anti-Idiotypic Antibodies

Keywords

  • Graft-versus-host disease
  • Mogamulizumab
  • Plasma exchange
  • Regulatory T cells

ASJC Scopus subject areas

  • Hematology

Cite this

Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels. / Sugiura, Hiroyuki; Matsuoka, Ken-ichi; Sando, Yasuhisa; Meguri, Yusuke; Ikegawa, Shuntaro; Nakamura, Makoto; Iwamoto, Miki; Yoshioka, Takanori; Asano, Takeru; Kondo, Eisei; Fujii, Keiko; Fujii, Nobuharu; Maeda, Yoshinobu.

In: Transfusion and Apheresis Science, 01.01.2019.

Research output: Contribution to journalArticle

Sugiura, Hiroyuki ; Matsuoka, Ken-ichi ; Sando, Yasuhisa ; Meguri, Yusuke ; Ikegawa, Shuntaro ; Nakamura, Makoto ; Iwamoto, Miki ; Yoshioka, Takanori ; Asano, Takeru ; Kondo, Eisei ; Fujii, Keiko ; Fujii, Nobuharu ; Maeda, Yoshinobu. / Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels. In: Transfusion and Apheresis Science. 2019.
@article{195b23799b1f48ae8a959748d259f133,
title = "Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels",
abstract = "Mogamulizumab (Mog), a humanized anti-CCR4 antibody, provides an important treatment option for relapsed/refractory adult T cell leukemia/lymphoma. However, administration of Mog before allogenic hematopoietic stem cell transplantation has been reported to be a risk factor for severe acute graft-versus-host disease (GVHD). The etiological hypothesis is Mogamulizumab may eradicate CCR4-positive regulatory T cells (Tregs). Theoretically, Treg homeostasis and course of GVHD can be affected by plasma exchange (PE) with decreasing plasma Mog concentration. Here, we present a case of severe acute GVHD after pretransplantation Mog, in which PE was performed for liver failure. As a result, plasma Mog concentration was decreased but it did not lead to the prompt elevation of Treg levels in peripheral blood and clinical responses of GVHD were limited to partial remission. Our case suggests that recovery of donor-derived Treg in the acute phase after HSCT is multifactorial and the single procedure of PE-based Mog depletion does not necessarily warrant the quick restoration of Treg homeostasis.",
keywords = "Graft-versus-host disease, Mogamulizumab, Plasma exchange, Regulatory T cells",
author = "Hiroyuki Sugiura and Ken-ichi Matsuoka and Yasuhisa Sando and Yusuke Meguri and Shuntaro Ikegawa and Makoto Nakamura and Miki Iwamoto and Takanori Yoshioka and Takeru Asano and Eisei Kondo and Keiko Fujii and Nobuharu Fujii and Yoshinobu Maeda",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.transci.2019.05.011",
language = "English",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels

AU - Sugiura, Hiroyuki

AU - Matsuoka, Ken-ichi

AU - Sando, Yasuhisa

AU - Meguri, Yusuke

AU - Ikegawa, Shuntaro

AU - Nakamura, Makoto

AU - Iwamoto, Miki

AU - Yoshioka, Takanori

AU - Asano, Takeru

AU - Kondo, Eisei

AU - Fujii, Keiko

AU - Fujii, Nobuharu

AU - Maeda, Yoshinobu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mogamulizumab (Mog), a humanized anti-CCR4 antibody, provides an important treatment option for relapsed/refractory adult T cell leukemia/lymphoma. However, administration of Mog before allogenic hematopoietic stem cell transplantation has been reported to be a risk factor for severe acute graft-versus-host disease (GVHD). The etiological hypothesis is Mogamulizumab may eradicate CCR4-positive regulatory T cells (Tregs). Theoretically, Treg homeostasis and course of GVHD can be affected by plasma exchange (PE) with decreasing plasma Mog concentration. Here, we present a case of severe acute GVHD after pretransplantation Mog, in which PE was performed for liver failure. As a result, plasma Mog concentration was decreased but it did not lead to the prompt elevation of Treg levels in peripheral blood and clinical responses of GVHD were limited to partial remission. Our case suggests that recovery of donor-derived Treg in the acute phase after HSCT is multifactorial and the single procedure of PE-based Mog depletion does not necessarily warrant the quick restoration of Treg homeostasis.

AB - Mogamulizumab (Mog), a humanized anti-CCR4 antibody, provides an important treatment option for relapsed/refractory adult T cell leukemia/lymphoma. However, administration of Mog before allogenic hematopoietic stem cell transplantation has been reported to be a risk factor for severe acute graft-versus-host disease (GVHD). The etiological hypothesis is Mogamulizumab may eradicate CCR4-positive regulatory T cells (Tregs). Theoretically, Treg homeostasis and course of GVHD can be affected by plasma exchange (PE) with decreasing plasma Mog concentration. Here, we present a case of severe acute GVHD after pretransplantation Mog, in which PE was performed for liver failure. As a result, plasma Mog concentration was decreased but it did not lead to the prompt elevation of Treg levels in peripheral blood and clinical responses of GVHD were limited to partial remission. Our case suggests that recovery of donor-derived Treg in the acute phase after HSCT is multifactorial and the single procedure of PE-based Mog depletion does not necessarily warrant the quick restoration of Treg homeostasis.

KW - Graft-versus-host disease

KW - Mogamulizumab

KW - Plasma exchange

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=85068667158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068667158&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2019.05.011

DO - 10.1016/j.transci.2019.05.011

M3 - Article

C2 - 31303512

AN - SCOPUS:85068667158

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

ER -